Your browser doesn't support javascript.
loading
Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease
Gil Candel, Mayte; Gascón Cánovas, Juan José; Urbieta Sanz, Elena; Gómez Espín, Rosa; Nicolás de Prado, Isabel; Iniesta Navalón, Carles.
Afiliação
  • Gil Candel, Mayte; Hospital General Universitario Reina Sofía. Department of Hospital Pharmacy. Murcia. Spain
  • Gascón Cánovas, Juan José; Universidad de Murcia. Department of Public Health. Murcia. Spain
  • Urbieta Sanz, Elena; Hospital General Universitario Reina Sofía. Department of Hospital Pharmacy. Murcia. Spain
  • Gómez Espín, Rosa; Hospital General Universitario Reina Sofía. Department of Gastroenterology. Murcia. Spain
  • Nicolás de Prado, Isabel; Hospital General Universitario Reina Sofía. Department of Gastroenterology. Murcia. Spain
  • Iniesta Navalón, Carles; Hospital General Universitario Reina Sofía. Department of Hospital Pharmacy. Murcia. Spain
Rev. esp. enferm. dig ; 112(5): 360-366, mayo 2020. tab, ilus
Article em En | IBECS | ID: ibc-195589
Biblioteca responsável: ES1.1
Localização: BNCS
ABSTRACT
INTRODUCTION: previous studies have shown that higher infliximab trough levels are associated with favorable shortterm and long-term therapeutic outcomes in inflammatory bowel disease. There is a need to determine which patients could benefit from proactive therapeutic drug monitoring in the induction phase. The aim of this study was to evaluate the pharmacokinetic variability of infliximab, determine the factors associated with achieving target infliximab trough levels in the induction phase and analyze the clinical and biochemical response at week 26 of treatment. PATIENTS AND METHODS: a retrospective observational study was performed of patients with inflammatory bowel disease and data available on serum levels of infliximab during the induction period. The percentage of patients that achieved target infliximab trough levels at week 6 was determined. Clinical remission and response and biochemical remission were evaluated at week 26. RESULTS: thirty patients were included and only 13 (43.3 %) had infliximab trough levels > 15 μg/mL at week 6. A clinical response was observed during the maintenance period in 71.4 % of patients, their infliximab levels were significantly higher than in non-responders (6.3 μg/mL [IQR: 6.7] vs 1.0 μg/mL [IQR: 5.0], respectively; p = 0.016). Likewise, 53.6 % of patients achieved biochemical remission (responders 6.2 μg/mL [IQR: 5.2] vs non-responders 3.2 μg/mL [IQR: 5.0]; p = 0.031). CONCLUSION: less than half of patients had target infliximab levels during the induction period. Therapeutic drug monitoring during this period is related to the achievement of therapeutic levels of infliximab and may lead to a better clinical response in these patients
RESUMEN
No disponible
Assuntos
Buscar no Google
Coleções: 06-national / ES Base de dados: IBECS Assunto principal: Fármacos Gastrointestinais / Doenças Inflamatórias Intestinais / Infliximab Limite: Adult / Aged / Female / Humans / Male Idioma: En Revista: Rev. esp. enferm. dig Ano de publicação: 2020 Tipo de documento: Article
Buscar no Google
Coleções: 06-national / ES Base de dados: IBECS Assunto principal: Fármacos Gastrointestinais / Doenças Inflamatórias Intestinais / Infliximab Limite: Adult / Aged / Female / Humans / Male Idioma: En Revista: Rev. esp. enferm. dig Ano de publicação: 2020 Tipo de documento: Article